Literature DB >> 28592425

Targeting Plasma Cells with Proteasome Inhibitors: Principles from Primates.

E Steve Woodle1,2, Simon Tremblay3,2, James Driscoll3,2.   

Abstract

Keywords:  B cell; HLA antibody; desensitization; plasma cell; proteasome inhibitor

Mesh：

Substances：

Year:  2017        PMID： 28592425      PMCID： PMC5491302          DOI： 10.1681/ASN.2017040443

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  13 in total

1.  The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats.

Authors:  Evangelia Yannaki; Anastasia Papadopoulou; Evangelia Athanasiou; Panayotis Kaloyannidis; Argyro Paraskeva; Dimitris Bougiouklis; Panayotis Palladas; Minas Yiangou; Achilles Anagnostopoulos
Journal:  Arthritis Rheum       Date:  2010-11

2.  Prospective iterative trial of proteasome inhibitor-based desensitization.

Authors:  E S Woodle; A R Shields; N S Ejaz; B Sadaka; A Girnita; R C Walsh; R R Alloway; P Brailey; M A Cardi; B G Abu Jawdeh; P Roy-Chaudhury; A Govil; G Mogilishetty
Journal:  Am J Transplant       Date:  2015-01       Impact factor: 8.086

3.  A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.

Authors:  Ravi K Anchoori; Balasubramanyam Karanam; Shiwen Peng; Joshua W Wang; Rosie Jiang; Toshihiko Tanno; Robert Z Orlowski; William Matsui; Ming Zhao; Michelle A Rudek; Chien-fu Hung; Xiang Chen; Kylie J Walters; Richard B S Roden
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

4.  Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.

Authors:  Alejandro M Gomez; Kathleen Vrolix; Pilar Martínez-Martínez; Peter C Molenaar; Marko Phernambucq; Eline van der Esch; Hans Duimel; Fons Verheyen; Reinhard E Voll; Rudolf A Manz; Marc H De Baets; Mario Losen
Journal:  J Immunol       Date:  2011-01-14       Impact factor: 5.422

5.  Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.

Authors:  Karin Polzer; Kirsten Neubert; Silke Meister; Benjamin Frey; Wolfgang Baum; Jörg H Distler; Eva Gückel; Georg Schett; Reinhard E Voll; Jochen Zwerina
Journal:  Arthritis Rheum       Date:  2011-03

6.  Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients.

Authors:  Jean Kwun; Christopher Burghuber; Miriam Manook; Neal Iwakoshi; Adriana Gibby; Jung Joo Hong; Stuart Knechtle
Journal:  J Am Soc Nephrol       Date:  2017-02-23       Impact factor: 10.121

7.  Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

Authors:  Matthew J Everly; Jason J Everly; Brian Susskind; Paul Brailey; Lois J Arend; Rita R Alloway; Prabir Roy-Chaudhury; Amit Govil; Gautham Mogilishetty; Adele H Rike; Michael Cardi; George Wadih; Amit Tevar; E Steve Woodle
Journal:  Transplantation       Date:  2008-12-27       Impact factor: 4.939

8.  Antibody-Mediated Rejection in Sensitized Nonhuman Primates: Modeling Human Biology.

Authors:  C K Burghuber; J Kwun; E J Page; M Manook; A C Gibby; F V Leopardi; M Song; A B Farris; J J Hong; F Villinger; A B Adams; N N Iwakoshi; S J Knechtle
Journal:  Am J Transplant       Date:  2016-03-25       Impact factor: 8.086

9.  Plasma cells negatively regulate the follicular helper T cell program.

Authors:  Nadége Pelletier; Louise J McHeyzer-Williams; Kurt A Wong; Eduard Urich; Nicolas Fazilleau; Michael G McHeyzer-Williams
Journal:  Nat Immunol       Date:  2010-10-31       Impact factor: 25.606

10.  Targeting plasma cells in autoimmune diseases.

Authors:  David M Tarlinton; Philip D Hodgkin
Journal:  J Exp Med       Date:  2004-06-01       Impact factor: 14.307
View more
  8 in total

1.  A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.

Authors:  Farsad Eskandary; Heinz Regele; Lukas Baumann; Gregor Bond; Nicolas Kozakowski; Markus Wahrmann; Luis G Hidalgo; Helmuth Haslacher; Christopher C Kaltenecker; Marie-Bernadette Aretin; Rainer Oberbauer; Martin Posch; Anton Staudenherz; Ammon Handisurya; Jeff Reeve; Philip F Halloran; Georg A Böhmig
Journal:  J Am Soc Nephrol       Date:  2017-12-14       Impact factor: 10.121

Review 2.  Experimental modeling of desensitization: What have we learned about preventing AMR?

Authors:  Jean Kwun; Stuart Knechtle
Journal:  Am J Transplant       Date:  2020-06       Impact factor: 8.086

Review 3.  Non-classical B Cell Memory of Allergic IgE Responses.

Authors:  Sean P Saunders; Erica G M Ma; Carlos J Aranda; Maria A Curotto de Lafaille
Journal:  Front Immunol       Date:  2019-04-26       Impact factor: 7.561

Review 4.  Therapies for Chronic Allograft Rejection.

Authors:  Min Young Kim; Daniel C Brennan
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 5.  Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies.

Authors:  Anna-Lena Mueller; Zahra Payandeh; Niloufar Mohammadkhani; Shaden M H Mubarak; Alireza Zakeri; Armina Alagheband Bahrami; Aranka Brockmueller; Mehdi Shakibaei
Journal:  Cells       Date:  2021-11-04       Impact factor: 6.600

Review 6.  Targeting Proteasomes in Cancer and Infectious Disease: A Parallel Strategy to Treat Malignancies and Microbes.

Authors:  James J Ignatz-Hoover; Elena V Murphy; James J Driscoll
Journal:  Front Cell Infect Microbiol       Date:  2022-07-07       Impact factor: 6.073

7.  Treatment of chronic active antibody-mediated rejection in renal transplant recipients - a single center retrospective study.

Authors:  Hsien-Fu Chiu; Mei-Chin Wen; Ming-Ju Wu; Cheng-Hsu Chen; Tung-Min Yu; Ya-Wen Chuang; Shih-Ting Huang; Shang-Feng Tsai; Ying-Chih Lo; Hao-Chung Ho; Kuo-Hsiung Shu
Journal:  BMC Nephrol       Date:  2020-01-06       Impact factor: 2.388

Review 8.  Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization.

Authors:  Ashley Y Choi; Miriam Manook; Danae Olaso; Brian Ezekian; Jaeberm Park; Kyle Freischlag; Annette Jackson; Stuart Knechtle; Jean Kwun
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.